medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (3)

Minoxidil as a treatment for alopecia: bibliographic review and practical guideline

Ruiz-Arriaga LF, Manríquez RA, Vega SDC, Arenas R, Guevara-Sanginés E

Language: Spanish
References: 44
Page: 350-357
PDF size: 291.95 Kb.


ABSTRACT

Minoxidil is a drug developed as an antihypertensive due to its vasodilator effect. It is approved worldwide for the topical treatment of androgenetic alopecia, for both male and female pattern, and for its positive effect on hair growth in other alopecias.
This review describes the pharmacokinetics, pharmacodynamics, pharmaceutical form, approved uses in dermatology, unapproved uses, contraindications, efficacy, and safety.
The most common questions associated with the use of minoxidil in clinical practice were collected and answered with the most recent and highest quality scientific evidence available.


REFERENCES

  1. Randolph M y Tosti A Oral minoxidil treatment for hair loss: a reviewof efficacy and safety, J Am Acad Dermatol 2021; 84(3):737-6.

  2. Heymann WR, Coming full circle (almost): low dose oral minoxidil foralopecia, J Am Acad Dermatol 2021; 84(3):613-4.

  3. Suchonwanit P, Thammarucha S y Leerunyakul K, Minoxidil and itsuse in hair disorders: a review, Drug Des Devel Ther 2019; 13:2777-86.

  4. Sinclair R, Trindade de Carvalho L, Ferial Ismail F y Meah N, Treatmentof male and female pattern hair loss with sublingual minoxidil:a retrospective case-series of 64 patients, J Eur Acad Dermatol Venereol2020; 34(12):e795-6.

  5. Pontes Cerqueira Uzel B, Soares Takano GH, Cabral Nunes Chartuni Jet al., Intradermal injections with 0.5% minoxidil for the treatment offemale androgenetic alopecia: a randomized, placebo-controlled trial,Dermatol Ther 2021; 34(1):e14622.

  6. El-Rahim Abdallah MA, Shareef R y Soltan MY, Efficacy of intradermalminoxidil 5% injections for treatment of patchy non-severe alopeciaareata, J Dermatolog Treat 2022; 33(2):1126-9.

  7. Merino de Paz N, Vázquez-Rodríguez C, Ramírez-Fernández G et al.,Mesotherapy with dutasteride and minoxidil in treatment of androgeneticalopecia, J Am Acad Dermatol 2018; 79(3):Sup1 ab190.

  8. Alsahi W, Alalola A, Randolph M et al., Novel drug delivery approachesfor the management of hair loss, Expert Opin Drug Deliv 2020;17(3):287-95.

  9. Angelo T, Barbalho GN, Gelfuso GM et al., Minoxidil topical treatmentmay be more efficient if applied on damp scalp in comparison withdry scalp, Dermatol Ther 2016; 29(5):330-3.

  10. Linas SL y Nies AS, Minoxidil, Ann Intern Med 1981; 94:61-5.

  11. Contin LA, Alopecia androgenética masculina tratada com microagulhamentoisolado e associado a minoxidil injetável pela técnica demicroinfusão de medicamentos pela pele, Surg Cosmet Dermatol 2016;8:158-61.

  12. Ramos PM, Gohad P, McCoy J, Wambier C y Goren A, Minoxidilsulfotransferase enzyme (sult1a1) genetic variants predicts responseto oral minoxidil treatment for female pattern hair loss, J Eur AcadDermatol Venereol 2021; 35(1):e24-6.

  13. Ramos PM, Goren A, Sinclair R y Miot HA, Oral minoxidil bio-activationby hair follicle outer root sheath cell sulfotransferase enzymespredicts clinical efficacy in female pattern hair loss, J Eur Acad DermatolVenereol 2020; 34(1):e40-1.

  14. Goren A y Naccarato T, Minoxidil in the treatment of androgeneticalopecia, Dermatol Ther 2018; 31(5):e12686.

  15. Goren A, Sharma A, Dhurat R, Shapiro J, Sinclair R, Situm M, KovacevicM, Lukinovic Skudar V, Goldust M, Lotti T y McCoy J, Low-dose dailyaspirin reduces topical minoxidil efficacy in androgenetic alopecia patients,Dermatol Ther 2018; 31(6):e12741.

  16. Villani A, Fabbrocini G, Ocampo-Candiani J, Ruggiero A y Ocampo-Garza SS, Review of oral minoxidil as treatment of hair disorders:in search of the perfect dose, J Eur Acad Dermatol Venereol 2021;35(7):1485-92.

  17. Katzer T, Leite Junior A, Beck R y Da Silva C, Physiopathology and currenttreatments of androgenetic alopecia: going beyond androgensand anti-androgens, Dermatol Ther 2019; 32(5):e13059.

  18. Beach RA, McDonald KA, Barrett BM y Abdel-Qadir H, Side effectsof low-dose oral minoxidil for treating alopecia, J Am Acad Dermatol,2021; 84(5):e239-40.

  19. Stoehr JR, Choi JN, Colavincenzo M y Vanderweil S, Off-label useof topical minoxidil in alopecia: a review, Am J Clin Dermatol 2019;

  20. 20:237-50.20. Olamiju B y Craiglow BG, Combination oral minoxidil and spironolactonefor the treatment of androgenetic alopecia in adolescent girls, JAm Acad Dermatol 2021; 84(6):1689-91.

  21. Lemes LR, Melo DF, De Oliveira DS, De La-Rocque M, Zompero C yRamos PM, Topical and oral minoxidil for hair disorders in pediatricpatients: what do we know so far, Dermatol Ther 2020:e13950.

  22. Sharma AN, Michelle L, Juhasz M, Muller Ramos P y AtanaskovaMesinkovska N, Low-dose oral minoxidil as treatment for non-scarringalopecia: a systematic review, Int J Dermatol 2020; 59(8):1013-9.

  23. Chen L, Zhang J, Wang L, Wang H y Chen B, The efficacy and safetyof finasteride combined with topical minoxidil for androgenetic alopecia: a systematic review and meta-analysis, Aesthetic Plast Surg 2020;44(3):962-70.

  24. Van Zuuren EJ y Fedorowicz Z, Interventions for female pattern hairloss, jama Dermatol 2017; 153:329-30.

  25. Ortega-Quijano D, Jiménez-Cauhe J, Fernández-Nieto D, Saceda-Corralo D y Vañó-Galvan S, Comment on “Low dose oral minoxidilfor treating alopecia: a 3-year North American retrospective case series”:adding further evidence about side effects, J Am Acad Dermatol2021; 84(5):e237-8.

  26. Gomolin A, Litvinov IV y Netchiporouk E, Oral minoxidil: a possiblenew therapy for androgenetic alopecia, J Cutan Med Surg 2020;24(1):88-9.

  27. Jha AK, Sonthalia S, Zeeshan MD y Vinay K, Efficacy and safety ofvery-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia, JAm Acad Dermatol 2020; 83(5):1491-3.

  28. Godwin M, The effectiveness of treatments for androgenetic alopecia:a systematic review and meta-analysis, J Am Acad Dermatol 2017;77(1):136-41.e5.

  29. Panchaprateep R y Lueangarun S, Efficacy and safety of oral minoxidil5 mg once daily in the treatment of male patients with androgeneticalopecia: an open-label and global photographic assessment, DermatolTher (Heidelberg) 2020; 10(6):1345-57.

  30. Pirmez R y Salas-Callo CI, Very-low-dose oral minoxidil in male androgeneticalopecia: a study with quantitative trichoscopic documentation,J Am Acad Dermatol 2020; 82(1):e21-2.

  31. Ramos PM, Sinclair RD, Kasprzak M y Miot HA, Minoxidil 1 mg oralversus minoxidil 5% topical solution for the treatment of female-patternhair loss: a randomized clinical trial, J Am Acad Dermatol 2020;82(1):252-3.

  32. Gupta AK, Venkataraman M, Talukder M et al., Relative efficacy ofminoxidil and the 5-α reductase inhibitors in androgenetic alopeciatreatment of male patients a network meta-analysis, jama Dermatol2022. doi: 10.1001/jamadermatol.2021.5743.

  33. Perera E y Sinclair R, Treatment of chronic telogen effluvium withoral minoxidil: a retrospective study, F1000Res. 2017; 6:1650.

  34. Vañó-Galván S, Trindade de Carvalho L, Saceda-Corralo D, Rodrigues-Barata R, Kerkemeyer KL, Sinclair RD, Hermosa-Gelbard Á, Moreno-Arrones ÓM, Jiménez-Cauhe J y Bhoyrul B, Oral minoxidil improvesbackground hair thickness in lichen planopilaris, J Am Acad Dermatol2021; 84(6):1684-6.

  35. Sanabria B, Vanzela TN, Miot HA y Müller Ramos P, Adverse effectsof low-dose oral minoxidil for androgenetic alopecia in 435 patients, JAm Acad Dermatol 2021; 84(4):1175-8.

  36. Freire PCB, Riera R, Martimbianco ALC, Petri V y Atallah AN, Minoxidilfor patchy alopecia areata: systematic review and meta-analysis, J EurAcad Dermatol Venereol 2019; 33(9):1792-9.

  37. Barton VR, Toussi A, Awasthi S y Kiuru M, Treatment of pediatricalopecia areata: a systematic review, J Am Acad Dermatol 2022; 86(6):1318-34.

  38. Bergfeld W, Washenik K, Callender V et al., A phase iii , multicenter,parallel-design clinical trial to compare the efficacy and safety of 5%minoxidil foam versus vehicle in women with female pattern hair loss,J Drugs Dermatol 2016; 15(7):874-81.

  39. Olsen EA, Whiting D, Bergfeld W et al., A multicenter, randomized,placebo-controlled, double-blind clinical trial of a novel formulationof 5% minoxidil topical foam versus placebo in the treatment of androgeneticalopecia in men, J Am Acad Dermatol 2007; 57(5):767-74.

  40. Sobota JT, Review of cardiovascular findings in humans treated withminoxidil, Toxicol Pathol 1989; 17(1 Pt 2):193-202.

  41. Callen EC, Church CO, Hernández CL et al., Stevens-Johnson syndromeassociated with oral minoxidil: a case report, J Nephrol 20: 91-3.

  42. Karaoui LR y Chahine-Chakhtoura C, Fatal toxic epidermal necrolysisassociated with minoxidil, Pharmacotherapy 2009; 29:460-7.

  43. Jiménez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernández-Nieto D y Vañó-GalvánS, Effectiveness and safety of low-dose oral minoxidil in male androgeneticalopecia, J Am Acad Dermatol 2019; 81(2):648-9.

  44. Moussa A, Kazmi A, Bokhari L et al., Bicalutamide improves minoxidilinducedhypertrichosis in female pattern hair loss: a retrospective reviewof 35 patients, J Am Acad Dermatol 2021; s0190-9622(21):2738-9.




2020     |     www.medigraphic.com